PSMA PET/CT for treatment response evaluation at predefined time points is superior to PSA response for predicting survival in metastatic castration-resistant prostate cancer patients
PSMA PET/CT for assessing treatment response at predefined time points was superior to PSA-based response for predicting overall survival in mCRPC patients treated with androgen receptor-targeted agents and chemotherapy. PSMA PET/CT showed the ability to detect disease progression earlier than PSA levels, which can affect treatment decisions and has the potential to improve patient outcomes. We recommend further research to validate these findings in larger patient cohorts, to extend the number of treatments, and to evaluate cost-effectiveness and impact on patient outcomes.
Authors
- Frits Smit (ORCID: https://orcid.org/0000-0003-2915-8613)
- Frank Toonen
- Jelle J. Goeman (ORCID: https://orcid.org/0000-0003-4283-0259)
- Lioe‐Fee de Geus‐Oei (ORCID: https://orcid.org/0000-0003-1817-2743)
- Saskia A. C. Luelmo (ORCID: https://orcid.org/0000-0002-9298-2878)
- Linda Heijmen (ORCID: https://orcid.org/0000-0003-1453-3337)
- Fleur Kleiburg (ORCID: https://orcid.org/0000-0003-4757-8777)
- Renske Spijkerman (ORCID: https://orcid.org/0000-0002-7831-5446)
- Tom van der Hulle (ORCID: https://orcid.org/0000-0002-2296-1828)
Institutions
- Leiden University Medical Center (NL)
- Alrijne Ziekenhuis (NL)
Publication Details
- Journal
- European Journal of Radiology
- Published
- 2024-10-02
- DOI
- https://doi.org/10.1016/j.ejrad.2024.111774
- Citations
- 16
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 6.70